β-Amyloid (25-35), HFIP-treated
Based on 45 publication(s) in Google Scholar
β-Amyloid (25-35) (Amyloid beta-peptide (25-35)), HFIP-treated is a β-Amyloid (25-35) (HY-P0128) treated with HFIP. β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells.
For research use only. We do not sell to patients.
- Purity: 98.18%
- CAS No.: 131602-53-4
- Formula: C45H81N13O14S
- Molecular Weight:1060.27
-
Storage:
Sealed storage, away from moisture.
Pure form -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) β-Amyloid (25-35), HFIP-treated
More- J Nanobiotechnology. 2024 Oct 19;22(1):642. [Abstract]
- Phytomedicine. 2026 Apr:153:157916. [Abstract]
- Phytomedicine. 2024 Dec:135:156041. [Abstract]
- ACS Sens. 2026 Jun 26;11(6):5047-5057. [Abstract]
- Acta Pharmacol Sin. 2026 Mar 19. [Abstract]
- Alzheimers Res Ther. 2025 May 15;17(1):104. [Abstract]
- Int J Biol Macromol. 2024 Aug 22;278(Pt 4):134972. [Abstract]
- Int J Nanomedicine. 2023 Nov 16:18:6797-6812. [Abstract]
- Phytother Res. 2023 Apr;37(4):1346-1365. [Abstract]
- Phytother Res. 2023 Feb;37(2):410-423. [Abstract]
- Am J Chin Med. 2025 Aug 30:1-32. [Abstract]
- J Ethnopharmacol. 2023 Sep 15:313:116550. [Abstract]
- J Ethnopharmacol. 2023 Aug 10:312:116455. [Abstract]
- CNS Neurosci Ther. 2026 Feb;32(2):e70771. [Abstract]
- Inflammopharmacology. 2025 Dec 6. [Abstract]
- Inflammopharmacology. 2024 Dec;32(6):3745-3759. [Abstract]
- Food Biosci. 2024 Dec.
- Int Immunopharmacol. 2026 Feb 1:170:116097. [Abstract]
- Neuropharmacology. 2025 Dec 14:286:110808. [Abstract]
- Brain Res Bull. 2026 Jun 7:243:111972. [Abstract]
- Neurochem Res. 2025 Apr 4;50(2):135. [Abstract]
- Brain Res Bull. 2024 Sep:215:111004. [Abstract]
- Neurochem Res. 2021 Sep;46(9):2376-2386. [Abstract]
- BMC Complement Med Ther. 2025 Mar 7;25(1):94. [Abstract]
- Front Cell Neurosci. 2021 Mar 25;15:614556. [Abstract]
- FASEB J. 2026 Mar 31;40(6):e71654. [Abstract]
- Neurotox Res. 2026 Mar 19;44(2):12. [Abstract]
- Metab Brain Dis. 2024 Oct;39(7):1433-1445. [Abstract]
- Hum Exp Toxicol. 2021 Dec;40(12_suppl):S347-S358. [Abstract]
- J Integr Neurosci. 2023 Jul 26;22(4):105. [Abstract]
- J Neurol Sci. 2020 Jun 15:413:116793. [Abstract]
- Fitoterapia. 2026 Apr:190:107162. [Abstract]
- Toxicol Res (Camb). 2023 Aug 7;12(5):756-764. [Abstract]
- Chem Biodivers. 2023 Jun;20(6):e202300430. [Abstract]
- Biomed Res Int. 2019 Apr 16:2019:4690280. [Abstract]
- J Mol Neurosci. 2020 Oct;70(10):1589-1597. [Abstract]
- Int J Neurosci. 2021 Feb;131(2):154-162. [Abstract]
- Eur J Inflamm. December 1, 2021.
- chemRxiv. 2026 Apr 24.
- Res Sq. 2025 Oct 20.
- Research Square Preprint. 2024 Apr 25.
- Research Square Preprint. 2024 Jan 5.
- Cell Mol Biol (Noisy-le-grand). 2024 Jan 31;70(1):200-206. [Abstract]
- Research Square Preprint. 2023 May 22.
- J Biomater Tissue Eng. 2021, pp. 295-301(7).
-
Cell Imaging/Staining
-
Flow Cytometry
-
ELISA
-
WB
-
IF
Biological Activity
The amino acid sequence of Aβ(25-35) peptide is NH2-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-COOH, where the first Gly represents the amino acid 25 and the last Met represents the amino acid 35. Amyloid beta-peptide(25-35) is also investigated in gel state for the first time. Comparative studies are also carried out using vibrational absorption and ECD. The conformational preference of Aβ(25-35) peptide film is also investigated using vibrational absorption and VCD spectroscopy[1].
Amyloid beta-peptide(25-35) induces apoptotic effects on isolated brain mitochondria and the redox state of methionine-35, plays a key role in the induction of programmed cellular death pathways and toxic events[2].
β-Amyloid Aggregation Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs).
1. The resulting film is dissolved in anhydrous DMSO at 5 mM and then dilutes into the appropriate concentration and buffer (serum- and phenol red-free culture medium) with vortexing.
2. Next, the solution is aged for 7 days at 37°C. The sample is then centrifuged at 14000g for 10 min at 4-8 °C; the soluble oligomers are in the supernatant. The supernatant is diluted 10-200-fold for experiments.
Methods vary depends on the downstream applications.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 131602-53-4
-
Appearance Solid-Liquid Mixture
-
Molecular Weight 1060.27
-
Formula C45H81N13O14S
-
Color Colorless to off-white
-
Synonyms
Amyloid beta-peptide (25-35), HFIP-treated; Aβ25-35, HFIP-treated; β-Amyloid peptide (25-35), HFIP-treated
-
Sequence
Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met
-
Sequence Shortening
GSNKGAIIGLM
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Pure form -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (45)
-
Journal Impact Factor
-
Most Recent
-
J Nanobiotechnology
A novel biomimetic nanovesicle containing caffeic acid-coupled carbon quantum dots for the the treatment of Alzheimer's disease via nasal administration. [Abstract]2024 Oct 19;22(1):642. PMID: 39425199
β-Amyloid (25-35), HFIP-treated purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Oct 19;22(1):642. [Abstract]
DCFH-DA probe fluorescence Images of different groups of BV2 cells induced by β-Amyloid (25-35)(Aβ; 10µM; 24 h) , scale bar =250 μm.
β-Amyloid (25-35), HFIP-treated purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Oct 19;22(1):642. [Abstract]
Flow cytometry detection of ROS in different groups including β-Amyloid (25-35)(Aβ; 10µM; 24 h) of BV2 cells.
β-Amyloid (25-35), HFIP-treated purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Oct 19;22(1):642. [Abstract]
Quantitative analysis of ELISA results for IL-1β, IL-6, TNF-α, and IL-10 in different groups including β-Amyloid (25-35)(Aβ; 10µM; 24 h) of BV2 cells.
β-Amyloid (25-35), HFIP-treated purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Oct 19;22(1):642. [Abstract]
Western blot analysis of IL-1β, IL-6, TNF-α, and IL-10 related pathological proteins in different groups including β-Amyloid (25-35)(Aβ; 10µM; 24 h) of BV2 cells.
β-Amyloid (25-35), HFIP-treated purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Oct 19;22(1):642. [Abstract]
Fluorescence images of IL-1β (I) and IL-6 (J) in different groups including β-Amyloid (25-35)(Aβ; 10µM; 24 h) of BV2 cells, scale bar = 50 μm.
β-Amyloid (25-35), HFIP-treated purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Oct 19;22(1):642. [Abstract]
Quantitative analysis of fluorescence curves for Thioflavin T (THT) detection of Aβ fiber aggregation in different groups including induction by β-Amyloid (25-35) (Aβ; 20 µM; 0-72 h) of BV2 cells.
β-Amyloid (25-35), HFIP-treated purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Oct 19;22(1):642. [Abstract]
Image of Annexin V-FITC apoptosis detection in different groups including β-Amyloid (25-35) (Aβ; 10 µM; 24 h) of SH-SY5Y cells.
-
Phytomedicine
Da-Bu-Yin-Wan rescues cognitive deficits in aging and Alzheimer's disease models by Wnt/β-catenin-dependent restoration of lysosomal acidification. [Abstract]2026 Apr:153:157916. PMID: 41662806 -
Phytomedicine
Jiawei Xionggui Decoction promotes meningeal lymphatic vessels clearance of β-amyloid by inhibiting arachidonic acid pathway. [Abstract]2024 Dec:135:156041. PMID: 39299091 -
ACS Sens
A Polarity-Sensitive Lipid Droplet Probe Reveals Aβ Species-Dependent Lipid Droplet Remodeling in Microglia. [Abstract]2026 Jun 26;11(6):5047-5057. PMID: 42263671 -
Acta Pharmacol Sin
Selective inhibition of monoamine oxidase B represents a therapeutic strategy for diabetic peripheral neuropathy. [Abstract]2026 Mar 19. PMID: 41857368 -
Alzheimers Res Ther
tRFAla-AGC-3-M8 attenuates neuroinflammation and neuronal damage in Alzheimer's disease via the EphA7-ERK1/2-p70S6K signaling pathway. [Abstract]2025 May 15;17(1):104. PMID: 40375351 -
Int J Biol Macromol
Chloride intracellular channel 4 blockade improves cognition in mice with Alzheimer's disease: CLIC4 protein expression and tau protein hyperphosphorylation. [Abstract]2024 Aug 22;278(Pt 4):134972. PMID: 39181373 -
Int J Nanomedicine
Functionalized Cerium Dioxide Nanoparticles with Antioxidative Neuroprotection for Alzheimer's Disease. [Abstract]2023 Nov 16:18:6797-6812. PMID: 38026525 -
Phytother Res
Neuroprotective effects of hawthorn leaf flavonoids in Aβ25-35 -induced Alzheimer's disease model. [Abstract]2023 Apr;37(4):1346-1365. PMID: 36447359 -
Phytother Res
3, 14, 19-Triacetyl Andrographolide alleviates the cognitive dysfunction of 3 × Tg-AD mice by inducing initiation and promoting degradation process of autophagy. [Abstract]2023 Feb;37(2):410-423. PMID: 36114804 -
Am J Chin Med
Identification of Flavonoid Compounds in Treating Alzheimer's Disease Based on Network Medicine Framework Strategy. [Abstract]2025 Aug 30:1-32. PMID: 40884807 -
J Ethnopharmacol
Neuroprotective effects of PRG on Aβ25-35-induced cytotoxicity through activation of the ERK1/2 signaling pathway. [Abstract]2023 Sep 15:313:116550. PMID: 37120057 -
J Ethnopharmacol
Loganin alleviated cognitive impairment in 3×Tg-AD mice through promoting mitophagy mediated by optineurin. [Abstract]2023 Aug 10:312:116455. PMID: 37019163 -
CNS Neurosci Ther
β-Asarone Attenuates Neuroinflammation of Alzheimer's Disease by Activating Autophagy and Suppressing NLRP3 Inflammasome Assembly. [Abstract]2026 Feb;32(2):e70771. PMID: 41635250 -
Inflammopharmacology
Neuroprotective effects of SRS11-92 against oxidative stress-induced senescence via Nrf2/HO-1/NF-κB in Alzheimer's disease models. [Abstract]2025 Dec 6. PMID: 41350486 -
Inflammopharmacology
A medicine and food homology formula prevents cognitive deficits by inhibiting neuroinflammation and oxidative stress via activating AEA-Trpv1-Nrf2 pathway. [Abstract]2024 Dec;32(6):3745-3759. PMID: 39305407 -
-
Int Immunopharmacol
Thymosin β4-derived peptides alleviate neuroinflammation and neurite atrophy in both in vitro models and in vivo 5 × FAD mice: A potential therapy for memory improvement in Alzheimer's disease. [Abstract]2026 Feb 1:170:116097. PMID: 41443105 -
Neuropharmacology
Cftr nominates a novel therapeutic target for Alzheimer's disease: Evidence from integrative omics and in vitro validation. [Abstract]2025 Dec 14:286:110808. PMID: 41401902 -
Brain Res Bull
Unveiling the multi-target mechanisms of Zuo Gui Wan in Alzheimer's disease: An integrated study combining network pharmacology, Mendelian Randomization, and molecular docking. [Abstract]2026 Jun 7:243:111972. PMID: 42259474 -
Neurochem Res
Targeting UAF1 Alleviate Neurotoxicity by Inhibiting APP/NLRP3 Axis-Mediated Pyroptosis and Apoptosis. [Abstract]2025 Apr 4;50(2):135. PMID: 40183841 -
Brain Res Bull
Hsa_circ_0049472 contributed to amyloid-beta peptide-induced neurotoxicity, apoptosis and inflammation via regulating PI3K-AKT signaling pathway by interacting with miR-22-3p/ZNF217 axis. [Abstract]2024 Sep:215:111004. PMID: 38852653 -
Neurochem Res
SRY-Box 21 Antisense RNA 1 Knockdown Diminishes Amyloid Beta25-35-Induced Neuronal Damage by miR-132/PI3K/AKT Pathway. [Abstract]2021 Sep;46(9):2376-2386. PMID: 34146195 -
BMC Complement Med Ther
Network pharmacology mechanism of Rosmarinus officinalis L.(Rosemary) to improve cell viability and reduces apoptosis in treating Alzheimer's disease. [Abstract]2025 Mar 7;25(1):94. PMID: 40055645 -
Front Cell Neurosci
IRE1α-XBP1 Affects the Mitochondrial Function of Aβ25-35-Treated SH-SY5Y Cells by Regulating Mitochondria-Associated Endoplasmic Reticulum Membranes. [Abstract]2021 Mar 25;15:614556. PMID: 33841100 -
FASEB J
Hypermethylation of FGF13 Reduces Microtubule Stability via Interaction With TUBB2A to Promote Mitochondrial Dysfunction in Alzheimer's Disease. [Abstract]2026 Mar 31;40(6):e71654. PMID: 41808420 -
Neurotox Res
Tubuloside B Alleviates Aβ25-35 Induced PC12 Cell Injury by Attenuating Pyroptosis, Apoptosis and Excessive Autophagy. [Abstract]2026 Mar 19;44(2):12. PMID: 41854817 -
Metab Brain Dis
Integrative analysis reveals key lysosomal genes as potential therapeutic targets in Alzheimer's disease. [Abstract]2024 Oct;39(7):1433-1445. PMID: 39150655 -
Hum Exp Toxicol
Notoginsenoside R2 reduces A β 25-35-induced neuronal apoptosis and inflammation via miR-27a/SOX8/ β-catenin axis. [Abstract]2021 Dec;40(12_suppl):S347-S358. PMID: 34533063 -
J Integr Neurosci
Bioinformatics and Experimental Identification of circ_0001535 Associated with Diagnosis and Development of Alzheimer's Disease. [Abstract]2023 Jul 26;22(4):105. PMID: 37519165 -
J Neurol Sci
2020 Jun 15:413:116793. PMID: 32251872 -
Fitoterapia
Exploring the effect of Kaixin San on Alzheimer's disease by regulating the Keap1/Nrf2/GPX4 signaling pathway to inhibit ferroptosis based on metabolomics and gut microbiota analysis. [Abstract]2026 Apr:190:107162. PMID: 41796868 -
Toxicol Res (Camb)
Scorpion venom heat-resistant peptide alleviates mitochondrial dynamics imbalance induced by PM2.5 exposure by downregulating the PGC-1α/SIRT3 signaling pathway. [Abstract]2023 Aug 7;12(5):756-764. PMID: 37915494 -
Chem Biodivers
Study on Calceolarioside A anti-Aβ25-35-induced Damage in SH-SY5Y Cells by Atomic Force Microscopy. [Abstract]2023 Jun;20(6):e202300430. PMID: 37166365 -
Biomed Res Int
Glutamine Improves Oxidative Stress through the Wnt3a/ β-Catenin Signaling Pathway in Alzheimer's Disease In Vitro and In Vivo. [Abstract]2019 Apr 16:2019:4690280. PMID: 31119171 -
J Mol Neurosci
MicroRNA-107 Ameliorates Damage in a Cell Model of Alzheimer's Disease by Mediating the FGF7/FGFR2/PI3K/Akt Pathway. [Abstract]2020 Oct;70(10):1589-1597. PMID: 32472396 -
Int J Neurosci
Vascular endothelial growth factor alleviates mitochondrial dysfunction and suppression of mitochondrial biogenesis in models of Alzheimer's disease. [Abstract]2021 Feb;131(2):154-162. PMID: 32083964 -
-
-
-
-
-
Cell Mol Biol (Noisy-le-grand)
Up-regulation of lncRNA WT1-AS ameliorates Aβ-stimulated neuronal injury through modulation of miR-186-5p/CCND2 axis in Alzheimer's disease. [Abstract]2024 Jan 31;70(1):200-206. PMID: 38372094 -
-
Solvent & Solubility
DMSO : 10 mg/mL (9.43 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
Cell viability is determined by a modified MTS assay, which is based on the conversion of Tetrazolium salt by mitochondrial dehydrogenase to a formazan product spectrophotometrically measurable at 490 nm. PC12 cells are plated in 96-well plates at a density of 10 000 cells/well and maintained for 16 h in complete medium. Cells are then incubated in the absence (control) and presence of 40 μM Aβ(31-35) and Aβ(25-35) with reduced, oxidized and norleucine-substituted methionine-35 staurosporine 10 μM is used as positive control of 100% of cellular death. After 48 h of peptide-incubation, 20 μL of MTS reagent (2.0 mg/mL) is added to each well. The cells are then incubated for 30-45 min at 37 °C in a 5% CO2 incubator. The reaction is stopped by adding 25 μL of 10% SDS. The plates are read with a microplate reader at 490 nm. Each data point is obtained using a triplet-well assay[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9432 mL | 4.7158 mL | 9.4316 mL | 23.5789 mL |
| 5 mM | 0.1886 mL | 0.9432 mL | 1.8863 mL | 4.7158 mL |